Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol-glycan biosynthesis class F protein (PIGF) is an enzyme that acts as a stabilizing subunit within the ethanolamine phosphate transferase complexes involved in the biosynthesis of glycosylphosphatidylinositol (GPI) anchors, which are glycolipids that tether proteins to the cell membrane. It specifically participates in the transfer of ethanolamine phosphate to the third and second mannose residues in the GPI precursor, in association with the PIGO and PIGG proteins. PIGF’s activity is crucial for the proper post-translational modification of surface proteins, especially in blood cells, and mutations in its gene can result in multiple congenital disorders affecting nails, bones, intellectual development, and seizure susceptibility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol-glycan biosynthesis class F protein (PIGF).